Ascendis Scores First Approval with Once-Weekly Pediatric GHD InjectorApprovals, Auto-Injection Therapy, Children, Clinical Trials, Drug Delivery, FDA, Growth Failure, Growth Hormone Deficiency (GHD), R&D, TherapeuticsThe U.S. Food and Drug Administration approved Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd) for children 1 year and older who have growth failure from inadequate secretion of endogenous growth hormone (GH). Read more August 26, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/08/Ascendis-Scores-First-Approval-with-Once-Weekly-Pediatric-GHD-Injector-BioSpace-8-26-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-08-26 16:55:322021-08-26 16:57:07Ascendis Scores First Approval with Once-Weekly Pediatric GHD Injector